Momenta Pharmaceuticals, Inc.
MNTA
MNTA was delisted on the 30th of September, 2020.
160 hedge funds and large institutions have $1.56B invested in Momenta Pharmaceuticals, Inc. in 2018 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 60 increasing their positions, 53 reducing their positions, and 21 closing their positions.
171% more call options, than puts
Call options by funds: $2.62M | Put options by funds: $969K
15% more capital invested
Capital invested by funds: $1.35B → $1.56B (+$207M)
13% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 53
2% less funds holding
Funds holding: 163 → 160 (-3)
14% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 21
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$79.5M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$62.7M |
| 3 |
BlackRock
New York
|
+$19.9M |
| 4 |
Franklin Resources
San Mateo,
California
|
+$18.8M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$109M |
| 2 |
Millennium Management
New York
|
-$12.1M |
| 3 |
GTC
Ghost Tree Capital
New York
|
-$9.07M |
| 4 |
JP Morgan Chase
New York
|
-$6.63M |
| 5 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$4.8M |
MNTA Hedge Fund Activity: Q2 2018 in Review
160 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Momenta Pharmaceuticals, Inc. (MNTA) for Q2 2018, worth a combined $1.56B — up 15% from $1.35B a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of MNTA and 18 opened new positions — a net loss of 3 holders — while 53 trimmed existing stakes and 60 added.
The largest buyer was RA Capital Management, opening a new position worth an estimated $79.5M. The largest seller was Wellington Management Group, cutting an estimated $109M.
- 160 institutional investors held Momenta Pharmaceuticals, Inc. (MNTA) as of Q2 2018, down from 163 in Q1 2018.
- Funds reported $1.56B of Momenta Pharmaceuticals, Inc. stock for Q2 2018, up 15% quarter-over-quarter.
- 18 funds opened new Momenta Pharmaceuticals, Inc. positions in Q2 2018 and 21 closed out, a net change of -3 holders.
- The largest Momenta Pharmaceuticals, Inc. buyer in Q2 2018 was RA Capital Management, an estimated $79.5M added.
- The largest Momenta Pharmaceuticals, Inc. seller in Q2 2018 was Wellington Management Group, an estimated $109M sold.
Based on aggregated 13F filings for Q2 2018.